



Groundbreaking **science**. Breakthrough **medicine**.™

Management Team

Martin McGlynn, President and Chief Executive Officer

Martin McGlynn joined StemCells, Inc. in January of 2001 as President and Chief Executive Officer and was elected to our Board of Directors on February 6, 2001. Mr. McGlynn has spent several decades in the life sciences industry in Europe, Canada and the United States. He began his career with Becton Dickinson, Ireland Ltd., and spent eight years in manufacturing operations. He joined Abbott Labs in 1977 where he held positions as General Manager, Abbott Ireland Ltd., President and General Manager of Abbott Canada Ltd. and Vice President of Abbott International Ltd. In 1990, he joined the BOC Group as President of Anaquest, Inc., a global leader in anesthesia and acute care pharmaceuticals headquartered in New Jersey. Mr. McGlynn joined the biotech industry in 1994 when he became President and Chief Executive Officer of Pharmadigm, Inc., a private, venture capital-backed company engaged in the research and development of a new class of anti-inflammatory agents. Mr. McGlynn is a native of Dublin, Ireland. He holds a Bachelor of Commerce degree from University College, Dublin. He is a former member of the Board of Directors of the Confederation of Irish Industries (CII) and the Pharmaceutical Manufacturers Association of Canada (PMAC), and currently serves as a member of the Board of the Alliance for Regenerative Medicine (ARM).

Rodney Young, Chief Financial Officer & Vice President, Finance and Administration

Rodney Young joined StemCells, Inc. in September 2005. He has overall responsibility for corporate financial management, financial reporting and controls, investor relations and information technology. Prior to joining StemCells, Mr. Young was Chief Financial Officer and a director of a private pharmaceutical company focused on developing drugs for pediatric indications, where he was responsible for all financial and administrative functions. Before joining the biotechnology industry, Mr. Young was Managing Director and head of health care corporate finance in Europe for SG Cowen Securities, and prior to that, he spent more than a decade at Lehman Brothers, where he was a senior investment banker in both the health care and mergers & acquisitions groups. Mr. Young earned his BA and MBA degrees from the University of Chicago.

Ann Tsukamoto, Ph.D., Executive Vice President, Research and Development

Ann Tsukamoto, Ph.D., was appointed Executive Vice President, Research and Development in September 2008. She previously served as Vice President, Research and Development. Dr. Tsukamoto has more than 20 years experience in stem cell biology and was a co-discoverer of the human hematopoietic stem cell while at SyStemix, Inc., and played a leading role in the launch of the clinical research program for the hematopoietic stem cell. Under her direction at StemCells Inc., the scientific team isolated the human neural stem cell, a population of human liver engrafting cells and a candidate pancreas stem cell. Dr. Tsukamoto received her Ph.D. from the University of California, Los Angeles and did postdoctoral research with Dr. Harold Varmus at the University of California, San Francisco where she worked on the wnt-1 gene, which is a key player in the stem cell self-renewal pathway. Dr. Tsukamoto is an inventor on six issued U.S. patents related to the human hematopoietic stem cell.

Stewart Craig, Ph.D., Senior Vice President, Development and Operations

Stewart Craig, Ph.D. joined StemCells, Inc. as Senior Vice President, Development & Operations in September 2008. He was previously Chief Technology Officer at Progenitor Cell Therapy, LLC (PCT), a contract service provider for the research, development, manufacture and commercialization of cell-based therapies. Prior to PCT, Dr. Craig served for 6 years as Chief Operating Officer at Xcyte Therapies, Inc., a company developing cell-based therapeutic products for the treatment of cancer, immune dysfunction and other diseases. Prior to Xcyte Therapies, Dr. Craig served as Vice President, Development & Operations at Osiris Therapeutics, a mesenchymal stem cell therapy company. During this time, Dr. Craig was also a member of the United States Pharmacopeia Expert Advisory Panel for Cell and Gene Therapy and was a co-author for the initial USP monograph on this subject. From 1994 - 1996, Dr. Craig served as Vice President, Product & Process Development at SyStemix, Inc., the pioneering California-based hematopoietic stem cell and gene therapy company. From 1987 - 1993, Dr. Craig served in various research and development positions at British Biotech, PLC, working on the design, purification and characterization of recombinant therapeutic protein molecules. Dr. Craig received his B.Sc. in Biochemistry and Ph.D. in Physical Biochemistry from the University of Newcastle upon Tyne, UK.

USA

3155 Porter Drive
Palo Alto, CA 94304 USA
T +1 (650) 475-3100 • F +1 (650) 475-3101

Europe

Minerva Building 250, Babraham Research Campus
Cambridge CB22 3AT United Kingdom
T +44 (0) 1223 499160 • F +44 (0) 1223 499178

Ken Stratton, General Counsel

Ken Stratton joined StemCells, Inc. as General Counsel in February 2007. His primary responsibilities include overseeing the Company's legal operations and advising the Company and its management and directors on various compliance matters. He also serves as corporate secretary. In March 2008, he assumed responsibilities for the Human Resources function. Mr. Stratton was formerly Deputy General Counsel at Threshold Pharmaceuticals, Inc., and prior to that was Senior Legal Counsel for the vascular business unit of Medtronic, Inc., an international medical device manufacturer. Prior to joining industry, Mr. Stratton was a business attorney in private practice for ten years handling both transactional and litigation matters with corporate law firms in San Francisco and Palo Alto. He earned both his J.D. and M.B.A. in finance from New York University and his B.A. from the University of Pennsylvania.

Stephen Huhn, M.D., F.A.C.S., F.A.A.P., Vice President, Head of the CNS Program

Stephen Huhn joined StemCells, Inc. in January 2007 to direct the Company's preclinical and clinical development programs for CNS indications. Prior to joining the company, he was an Associate Professor of Neurosurgery at Stanford University and Chief of Pediatric Neurosurgery at the Lucile Salter Packard Children's Hospital. Dr. Huhn earned his M.D. at the University of Arizona in 1987 and completed a residency in Neurosurgery at the University of Maryland in 1993. He completed a fellowship in Neuro-Oncology at UCSF Medical Center in San Francisco and a fellowship in Pediatric Neurosurgery at Children's Memorial Hospital in Chicago, Northwestern University. Dr. Huhn is certified by the American Board of Neurological Surgery and the American Board of Pediatric Neurological Surgery. He is also a Fellow in the American College of Surgeons and the American Academy of Pediatrics. Dr. Huhn maintains a Consulting Associate Professor appointment (without salary) with the Department of Neurosurgery at Stanford University.

Maria Millan, M.D., F.A.C.S., Vice President, Head of the Liver Program

Maria Millan joined StemCells, Inc. in January 2006 and was promoted to Vice President, Head of the Liver Program in December 2006. She is responsible for managing the pre-clinical and clinical development programs for liver indications. Dr. Millan is also serving as the Company's Acting Chief Medical Officer. She previously was Associate Professor of Surgery, Division of Multi-Organ Transplant, and Director of Pediatric Transplant Programs, Kidney & Liver, at Stanford University School of Medicine, and continues to maintain her appointment as an Adjunct Associate Professor. She received her MD from the New Jersey Medical School and was a Resident and Chief Resident in General Surgery at Harvard Medical School/New England Deaconess Hospital and the Beth Israel Deaconess Medical Center in Boston, Mass. She received a research fellowship in Immunobiology at Harvard Medical School, and held a Fellowship in Multi-Organ Transplant Surgery at Stanford.

Nobuko Uchida, Ph.D., Vice President, Stem Cell Biology

Nobuko Uchida is responsible for the Company's discovery initiative focusing on identifying new stem or progenitor cells, as well as for characterizing the Company's human neural stem cell and candidate liver and pancreas stem cells. Dr. Uchida has been with the Company since 1998, and in 1999 she was first to identify, by a combination of cell surface markers, the human neural stem cell. Dr. Uchida was previously employed at SyStemix, Inc. as a research scientist working on hematopoietic stem cell biology, and has worked in stem cell biology for the past 15 years. Dr. Uchida obtained her Ph.D. in Cancer Biology from Stanford University and completed her post doctoral training in the laboratory of Dr. Irving Weissman at the Stanford University School of Medicine.

Dennise Dalma-Weiszhausz, Ph.D., Vice President of Research & Development Services

Dennise Dalma-Weiszhausz, Ph.D. joined StemCells, Inc. in 2007. Dr. Dalma-Weiszhausz is responsible for leading the Company's Research & Development Services group, assessing technologies and their commercial potential, identifying strategic alliances, and overseeing funding initiatives for various research and development programs. She previously was employed as General Manager of Vivotics, Inc., a start-up biotechnology company focused on molecular beacon technology. Prior to that, Dr. Dalma-Weiszhausz managed marketing and business development for Affymetrix, Inc., a leading biotools company focused on high throughput whole-genome analyses. Dr. Dalma-Weiszhausz completed her post-doctoral training in the Department of Molecular Biophysics and Biochemistry at Yale University. She earned her Ph.D. and M.Phil. in biochemistry from Albert Einstein College of Medicine, her M.Sci. in Molecular Biophysics and Biochemistry from Yale University, and her B.Sc. in Biomedical Research from Universidad Nacional Autonoma de Mexico. She has authored a variety of papers and reviews in the genomics field.

Board of Directors

John J. Schwartz, Ph.D.
Chairman of the Board
President, Quantum Strategies Management

John Schwartz was elected to the Board of Directors of StemCells, Inc. in December 1998 and was elected the Chairman of the Board at the same time. He is the former President and Chief Executive Officer of SyStemix, Inc. Dr. Schwartz is currently the President of Quantum Strategies Management Company, a registered investment advisor located in Palo Alto, California. Prior to his positions at SyStemix, he served as Assistant Professor, Vice President and General Counsel at Stanford University in California. Dr. Schwartz graduated from Harvard Law School in 1958 and received his Ph.D. degree in physics from the University of Rochester in 1965.

Eric H. Bjerkholt
Senior Vice President and CFO, Sunesis Pharmaceuticals, Inc.

Eric Bjerkholt was elected to the Board of Directors of StemCells, Inc. in March 2004. He is Senior Vice President and Chief Financial Officer of Sunesis Pharmaceuticals, Inc., a small molecule biopharmaceutical company in South San Francisco, California. Before joining Sunesis, Mr. Bjerkholt served as the Senior Vice President and Chief Financial Officer of IntraBiotics Pharmaceuticals, Inc. Previously, Mr. Bjerkholt co-founded LifeSpring Nutrition, Inc., a privately held nutraceutical company, and served as its Chief Financial Officer, and later as its President and Chief Executive Officer. From 1990 to 1997, Mr. Bjerkholt was an investment banker at J.P. Morgan & Co., Inc. Mr. Bjerkholt holds an M.B.A. from Harvard Business School and a Cand. Oecon degree in economics and econometrics from the University of Oslo, Norway. He is a member of the board of directors of Round Table Pizza, Inc.

R. Scott Greer
Principal & Managing Director, Numenor Ventures LLC

R. Scott Greer was elected to the Board of Directors of the Company in June 2010, and was simultaneously appointed to Chair the Company's Strategic Transactions Committee. Mr. Greer is currently a principal and managing director of Numenor Ventures LLC, which he founded in 2002 to provide funding and strategic advisory services to early stage enterprises. He is also an investor and consultant to CEOs and founders of companies in various stages of development. Previously, Mr. Greer was founder of Abgenix, Inc., a biotechnology company that pioneered the development of antibodies as therapeutics, and served as its Chief Executive Office from its inception in 1996 until 2002, and as its Chairman from 2000 until 2006. Abgenix was acquired by Amgen in 2006 for \$2.2 billion. Prior to Abgenix's formation, Mr. Greer held senior management positions at Cell Genesys, Inc. including Senior Vice President, Corporate Development and Chief Financial Officer, and held various positions at Genetics Institute (acquired by Wyeth). Mr. Greer currently serves as Chairman of Acologix, a development stage biotechnology company, and is also on the board of Nektar Therapeutics and BAROnova. In the past, Mr. Greer served on several other public and private company boards, including Sirna Therapeutics (acquired by Merck), where he served as Chairman of the Board, Affymax, Anaptys Biosciences, Illumina, Chimeros, Inogen, and CV Therapeutics (acquired by Gilead Sciences). Mr. Greer received a B.A. in Economics from Whitman College and an M.B.A. from Harvard University, and was also a Certified Public Accountant.

Ricardo Levy, Ph.D.
Retired Founder, Chairman & CEO, Catalytica, Inc.

Ricardo Levy was elected to the Board of Directors of StemCells, Inc. in September 2001. He most recently served as Lead Director of Renegy Holdings, the successor of Catalytica Energy Systems, Inc., an environmental emissions solutions provider. Prior to his role with Renegy Holdings, Dr. Levy served as Chairman of the Board of Catalytica Energy Systems from 1995, when the company was formed as a subsidiary of Catalytica, Inc., until October 2007 when the company merged to form Renegy. Dr. Levy was a founder of Catalytica, Inc. in 1974, serving as Chief Operating Officer from 1974 until 1991, and President and Chief Executive Officer until December 2000, when Catalytica, Inc. and its subsidiary Catalytica Pharmaceuticals, Inc. were sold to DSM N.V. Before founding Catalytica, Inc., Dr. Levy was a founding member of Exxon's chemical physics research team, and prior to that served as Chief Executive Officer of Sudamericana C.A. in Quito, Ecuador. He continues to serve as Special Advisor to the Board of Directors of Renegy Holdings, and also as a member of the Board of Directors of Accelrys Inc. (formerly Pharmacopeia, Inc.) and NovoDynamics, Inc., a private company focused on advanced image discovery. Dr. Levy holds Bachelor of Science and PhD degrees in Chemical Engineering from Stanford University, and a Master of Science Degree from Princeton University.

Roger Perlmutter, M.D., Ph.D.
Executive Vice President, Research & Development, Amgen, Inc.

Roger Perlmutter was elected to the Board of Directors of StemCells, Inc. in December 2000. Dr. Perlmutter is the Executive Vice President of Research and Development of Amgen, Inc., a position he has held since January 2001. Prior to joining Amgen, he was the Executive Vice President of Worldwide Basic Research and Preclinical Development of Merck Research Laboratories, a division of Merck & Co., Inc., a position he had held since August 1999. He joined Merck in February 1997 as the Senior Vice President of Merck Research Laboratories, from February 1997 to December 1998 and as its Executive Vice President from February 1999 to January 2001. Prior to joining Merck, Dr. Perlmutter was a professor in the Departments of Immunology, Biochemistry and Medicine at the University of Washington from January 1991 to January 1997 and served as Chairman of the Department of Immunology at the University of Washington from May 1989 to January 1997. He also was an investigator at the Howard Hughes Medical Institute from October 1991 to January 1997. Dr. Perlmutter was a member of the Board of Directors of The Irvington Institute for Immunological Research from 1997 to 2001 and of the Institute for Systems Biology, where he has been its Chairman of the Board since 1999. Dr. Perlmutter is licensed to practice medicine in the State of Washington. He graduated from Reed College in 1973 and received his M.D. and Ph.D. degrees from Washington University, St. Louis, Missouri in 1979.

Irving L. Weissman, M.D.
Professor of Pathology and Developmental Biology, Stanford University

Irving L. Weissman is Professor of Pathology and Developmental Biology at Stanford University, Director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine and Director of the Stanford Ludwig Center for Cancer Stem Cell Research. Among his many scientific achievements, Dr. Weissman's laboratory was the first to discover the mammalian stem cell and the hematopoietic (blood-forming) stem cell. Dr. Weissman was also responsible for the formation of three stem cell companies: SyStemix, Inc., StemCells, Inc., and Cellerant, Inc. He is a member of the Board of Directors and the Scientific Advisory Board of StemCells. Professor Weissman received his B.S. from Montana State College in 1961 and an M.D. from Stanford University in 1965. During medical school he conducted research on thymus cell migration for nine months with Sir James Gowans at Oxford University, England. He was a postdoctoral fellow in Dr. H. S. Kaplan's laboratory at Stanford University from 1965-1967, and was appointed as a Research Associate in the Department of Radiology upon completion of the fellowship. He was appointed Assistant Professor of Pathology, Stanford School of Medicine in 1969, Associate Professor in 1974, and Professor in 1981. He was an Investigator of the Howard Hughes Medical Institute from 1990-1992. He was the Karel Beekhuis Professor of Cancer Biology from 1987 until 2005 and the Chair of the Immunology Program, a degree-granting program from 1986-2001. In 2002 he became Director of the Stanford Cancer/Stem Cell Institute, which was split into the Stanford Institute of Stem Cell Biology and Regenerative Medicine, and the Stanford Cancer Center in 2003; Weissman was Director of both, and was principal investigator on the successful NCI Cancer Center grant. He stepped down as Cancer Center Director in 2008, but remains director of the Stem Cell Institute. In May 2005, he was named the Virginia and D. K. Ludwig Professor for Clinical Investigation in Cancer Research. Professor Weissman is an elected member of the National Academy of Sciences (1989-present), the Institute of Medicine at the National Academy (2002-present), the American Academy of Arts and Sciences (1990-present), The American Association for the Advancement of Science (1990), the American Academy of Microbiology (1997-present), and the American Philosophical Society (2008-Present), and also served as President of the International Society of Stem Cell Research (ISSCR) from 2009 to 2010. Professor Weissman has received numerous awards for his many achievements throughout his career.

Scientific Advisory Board Members

PIONEERS IN STEM CELL DISCOVERY

Our scientific advisory board members, Irving Weissman, M.D., Fred Gage, Ph.D., and David Anderson, Ph.D., were responsible for the discovery of the mammalian blood, brain and peripheral nervous system stem cells, respectively, and continue to make significant contributions to the Company's research.

Irving L. Weissman, M.D.

Irving L. Weissman is Professor of Pathology and Developmental Biology at Stanford University, Director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine and Director of the Stanford Ludwig Center for Cancer Stem Cell Research. Among his many scientific achievements, Dr. Weissman's laboratory was the first to discover the mammalian stem cell and the hematopoietic (blood-forming) stem cell. Dr. Weissman was also responsible for the formation of three stem cell companies: SyStemix, Inc., StemCells, Inc., and Cellerant, Inc. He is a member of the Board of Directors and the Scientific Advisory Board of StemCells. Professor Weissman received his B.S. from Montana State College in 1961 and an M.D. from Stanford University in 1965. During medical school he conducted research on thymus cell migration for nine months with Sir James Gowans at Oxford University, England. He was a postdoctoral fellow in Dr. H. S. Kaplan's laboratory at Stanford University from 1965-1967, and was appointed as a Research Associate in the Department of Radiology upon completion of the fellowship. He was appointed Assistant Professor of Pathology, Stanford School of Medicine in 1969, Associate Professor in 1974, and Professor in 1981. He was an Investigator of the Howard Hughes Medical Institute from 1990-1992. He was the Karel Beekhuis Professor of Cancer Biology from 1987 until 2005 and the Chair of the Immunology Program, a degree-granting program from 1986-2001. In 2002 he became Director of the Stanford Cancer/Stem Cell Institute, which was split into the Stanford Institute of Stem Cell Biology and Regenerative Medicine, and the Stanford Cancer Center in 2003; Weissman was Director of both, and was principal investigator on the successful NCI Cancer Center grant. He stepped down as Cancer Center Director in 2008, but remains director of the Stem Cell Institute. In May 2005, he was named the Virginia and D. K. Ludwig Professor for Clinical Investigation in Cancer Research. Professor Weissman is an elected member of the National Academy of Sciences (1989-present), the Institute of Medicine at the National Academy (2002-present), the American Academy of Arts and Sciences (1990-present), The American Association for the Advancement of Science (1990), the American Academy of Microbiology (1997-present), and the American Philosophical Society (2008-Present), and also served as President of the International Society of Stem Cell Research (ISSCR) from 2009 to 2010. Professor Weissman has received numerous awards for his many achievements throughout his career.

Fred Gage, Ph.D.

Fred H. Gage is the head of the Laboratory of Genetics at the Salk Institute for Biological Studies, and Vi and John Adler Chair for Research on Age-Related Neurodegenerative Diseases and an Adjunct Professor in the Department of Neurosciences, at the University of California, San Diego in La Jolla, California. Dr. Gage's lab was the first to discover the mammalian central nervous system stem cell. His work concentrates on the adult central nervous system and unexpected plasticity and adaptability to environmental stimulation that remains throughout the life of all mammals. In addition, his studies focus on the cellular, molecular, as well as environmental influences that regulate neurogenesis in the adult. Dr. Gage has won numerous prizes and awards for his work including the IPSEN Prize for Neuroplasticity, the Charles A. Dana Award, Metropolitan Life Research Award and the Keio Medical Science Prize. He serves on many health related boards, and was President of the Society for Neuroscience and is President-Elect of the International Society for Stem Cell Research. Dr. Gage is a Fellow of the American Association for the Advancement of Science, a Member of the National Academy of Sciences and the Institute of Medicine, a Member of the American Academy of Arts and Sciences, a member of the American Philosophical Society and an Associate Member of the European Molecular Biology Organization.

David J. Anderson, Ph.D.

David J. Anderson is Seymour Benzer Professor of Biology at the California Institute of Technology and an Investigator of the Howard Hughes Medical Institute. His laboratory was the first to isolate a multipotent, self-renewing, stem cell for the peripheral nervous system, the first to identify instructive signals that promote the differentiation of these stem cells along various lineages, and the first to accomplish a direct purification of peripheral neural stem cells from uncultured tissue. Dr. Anderson received an A.B. degree at Harvard and a Ph.D. Degree at Rockefeller University where he trained with Nobelist Günter Blobel. Dr. Anderson performed postdoctoral studies at Columbia University with Nobelist Richard Axel. Awards: Helen Hay Whitney Foundation Fellow, 1983-86; NSF Presidential Young Investigator Award 1986-87; Searle Scholars Award, 1987-88; Alfred P. Sloan research Fellowship in Neuroscience, Javits Investigator in Neuroscience (NIH), 1989-96; Charles Judson Herrick Award in Comparative Neurology, 1990; Ferguson Award for Graduate Teaching, 1994; Ferguson Award for Biology Education, 1996; Ferguson Award for Graduate Teaching, 1998; Alden Spencer Award in Neurobiology, Columbia University, 1999; Elected Associate, The Neurosciences Institute, 2001; American Academy of Arts and Sciences Fellow, 2002; American Association for the Advancement of Science Fellow, 2002; Named Roger W. Sperry Professor of Biology, Caltech, 2004; Alexander von Humboldt Award, 2005; Elected to the National Academies of Sciences, 2007; Named Seymour Benzer Professor of Biology, Caltech, 2009.